BioLineRx annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx Return on Equity (ROE) Growth & History (BLRX)
BioLineRx's return on equity was −12.80% for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −12.80% | +56.31 pp |
| 2024 | 2024-12-31 | −69.11% | +120.12 pp |
| 2023 | 2023-12-31 | −189.23% | −147.27 pp |
| 2022 | 2022-12-31 | −41.96% | +18.08 pp |
| 2021 | 2021-12-31 | −60.04% | +48.32 pp |
| 2020 | 2020-12-31 | −108.36% | −40.23 pp |
| 2019 | 2019-12-31 | −68.13% | −19.38 pp |
| 2018 | 2018-12-31 | −48.75% | +6.65 pp |
| 2017 | 2017-12-31 | −55.40% | −17.06 pp |
| 2016 | 2016-12-31 | −38.34% | — |
BioLineRx quarterly return on equity
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −19.88% | −0.63 pp |
| Q1 2026 | 2026-03-31 | −9.18% | −39.06 pp |
| Q4 2025 | 2025-12-31 | −7.34% | — |
| Q3 2025 | 2025-09-30 | −4.93% | — |
| Q2 2025 | 2025-06-30 | −19.25% | −22.82 pp |
| Q1 2025 | 2025-03-31 | 29.88% | — |
| Q2 2024 | 2024-06-30 | 3.57% | +55.16 pp |
| Q2 2023 | 2023-06-30 | −51.59% | −39.65 pp |
| Q2 2022 | 2022-06-30 | −11.94% | +2.32 pp |
| Q2 2021 | 2021-06-30 | −14.27% | +7.36 pp |
| Q2 2020 | 2020-06-30 | −21.63% | −8.43 pp |
| Q2 2019 | 2019-06-30 | −13.20% | −3.53 pp |
| Q2 2018 | 2018-06-30 | −9.67% | — |
BioLineRx return on equity trends
Over the last five fiscal years, BioLineRx's return on equity increased from −108.36% to −12.80%, a change of +95.56 percentage points. The latest reported quarter, Q2 2026, shows −19.88%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗